Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial

Autor:	Ronald van Vollenhoven, Vibeke Strand, Tsutomu Takeuchi, Nilmo Chávez, Pablo Mannucci Walter, Atul Singhal, Jerzy Swierkot, Nasser Khan, Xianwei Bu, Yihan Li, Sara K. Penn, Heidi S. Camp, Jacob Aelion
Jazyk:	angličtina
Rok vydání:	2024
Předmět:	JAK inhibitor Methotrexate Targeted synthetic DMARD Upadacitinib Rheumatoid arthritis Randomized controlled trial Diseases of the musculoskeletal system RC925-935
Zdroj:	Arthritis Research & Therapy, Vol 26, Iss 1, Pp 1-15 (2024)
Druh dokumentu:	article
ISSN:	1478-6362
DOI:	10.1186/s13075-024-03358-x
Popis:	Abstract Background To evaluate the efficacy and safety of upadacitinib monotherapy versus methotrexate (MTX) monotherapy over 5 years among MTX-naïve patients with moderately to severely active rheumatoid arthritis (RA) in the long-term extension (LTE) of the phase 3 SELECT-EARLY trial. Methods Patients were randomized to receive upadacitinib 15 mg or 30 mg or MTX. Patients who did not achieve CDAI remission and had
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/d96238b03a104e99a640cf8bd22d5e92 Zobrazit plný text záznamu Full text from SpringerLink View record in DOAJ